Good Cascade Impactor Practice (GCIP) and considerations for "in-use" specifications
- PMID: 23344853
- PMCID: PMC3581645
- DOI: 10.1208/s12249-012-9905-1
Good Cascade Impactor Practice (GCIP) and considerations for "in-use" specifications
Abstract
The multi-stage cascade impactor (CI) is widely used to determine aerodynamic particle size distributions (APSDs) of orally inhaled products. Its size-fractionating capability depends primarily on the size of nozzles of each stage. Good Cascade Impactor Practice (GCIP) requires that these critical dimensions are linked to the accuracy of the APSD measurement based on the aerodynamic diameter size scale. Effective diameter (Deff) is the critical dimension describing any nozzle array, as it is directly related to stage cut-point size (d50). d50 can in turn be determined by calibration using particles of known aerodynamic diameter, providing traceability to the international length standard. Movements in Deff within manufacturer tolerances for compendial CIs result in the worst case in shifts in d50 of <±10%. Stage mensuration therefore provides satisfactory control of measurement accuracy. The accurate relationship of Deff to d50 requires the CI system to be leak-free, which can be checked by sealing the apparatus at the entry to the induction port and isolating it from the vacuum source and measuring the rate of pressure rise before each use. Mensuration takes place on an infrequent basis compared with the typical interval between individual APSD determinations. Measurement of stage flow resistance (pressure drop; ΔPstage) could enable the user to know that the CI stages are fit for use before every APSD measurement, by yielding an accurate measure of Deff. However, more data are needed to assess the effects of wear and blockage before this approach can be advocated as part of GCIP.
Figures





Similar articles
-
Measurement of Aerodynamic Particle Size Distribution of Orally Inhaled Products by Cascade Impactor: How to Let the Product Specification Drive the Quality Requirements of the Cascade Impactor.AAPS PharmSciTech. 2019 Jan 8;20(2):57. doi: 10.1208/s12249-018-1276-9. AAPS PharmSciTech. 2019. PMID: 30623259 Review.
-
Relationship of stage mensuration data to the performance of new and used cascade impactors.J Aerosol Med. 2005 Winter;18(4):396-413. doi: 10.1089/jam.2005.18.396. J Aerosol Med. 2005. PMID: 16379616
-
Particle Size Measurements from Orally Inhaled and Nasal Drug Products.J Aerosol Med Pulm Drug Deliv. 2021 Dec;34(6):325-345. doi: 10.1089/jamp.2021.29047.jpm. J Aerosol Med Pulm Drug Deliv. 2021. PMID: 34860563
-
Determination of Passive Dry Powder Inhaler Aerodynamic Particle Size Distribution by Multi-Stage Cascade Impactor: International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) Recommendations to Support Both Product Quality Control and Clinical Programs.AAPS PharmSciTech. 2019 May 30;20(5):206. doi: 10.1208/s12249-019-1416-x. AAPS PharmSciTech. 2019. PMID: 31147791
-
Addressing the Need for Controls on Particle Bounce and Re-entrainment in the Cascade Impactor and for the Mitigation of Electrostatic Charge for Aerodynamic Particle Size Assessment of Orally Inhaled Products: an Assessment by the International Consortium on Regulation and Science (IPAC-RS).AAPS PharmSciTech. 2020 Aug 21;21(7):239. doi: 10.1208/s12249-020-01720-1. AAPS PharmSciTech. 2020. PMID: 32827121 Review.
Cited by
-
In Vitro Analysis of Aerodynamic Properties and Co-Deposition of a Fixed-Dose Combination of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate.Pharmaceutics. 2024 Oct 18;16(10):1334. doi: 10.3390/pharmaceutics16101334. Pharmaceutics. 2024. PMID: 39458663 Free PMC article.
-
Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.Kona. 2016 Feb 28;33:63-85. doi: 10.14356/kona.2016014. Epub 2015 Sep 30. Kona. 2016. PMID: 27081214 Free PMC article.
-
Particle sizing of pharmaceutical aerosols via direct imaging of particle settling velocities.Eur J Pharm Sci. 2018 Feb 15;113:152-158. doi: 10.1016/j.ejps.2017.08.016. Epub 2017 Aug 16. Eur J Pharm Sci. 2018. PMID: 28821437 Free PMC article.
-
Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.Int J Mol Sci. 2022 Feb 22;23(5):2408. doi: 10.3390/ijms23052408. Int J Mol Sci. 2022. PMID: 35269550 Free PMC article. Review.
-
Multivariate Analysis of Effects of Asthmatic Patient Respiratory Profiles on the In Vitro Performance of a Reservoir Multidose and a Capsule-Based Dry Powder Inhaler.Pharm Res. 2016 Mar;33(3):701-15. doi: 10.1007/s11095-015-1820-1. Epub 2015 Nov 16. Pharm Res. 2016. PMID: 26572643 Free PMC article.
References
-
- Newman SP, Chan H-K. In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med. 2008;21(1):1–8. - PubMed
-
- European Directorate for Quality in Medicines and HealthCare (EDQM). Monograph 2.9.18: European Pharmacopeia, Preparations for inhalation: aerodynamic assessment of fine particles, Council of Europe, 67075 Strasbourg, France, 2012; Ph.Eur.7.5 [USB 7th ed. (7.52012)].
-
- United States Pharmacopeial Convention. Chapter 601: Aerosols, Nasal Sprays, Metered-Dose Inhalers and Dry Powder Inhalers. Rockville, MD, USA, 2012; USP 35-NF 30.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources